Lenvima (lenvatinib) / Eisai, Merck (MSD) 
Welcome,         Profile    Billing    Logout  
 53 Diseases   490 Trials   490 Trials   8927 News 


«12...3738394041424344454647...123124»
  • ||||||||||  Mekinist (trametinib) / Novartis, BeiGene, Lenvima (lenvatinib) / Eisai, Merck (MSD)
    Trial completion date, Trial primary completion date, Metastases:  Trametinib Combined With Everolimus and Lenvatinib for Recurrent/Refractory Advanced Solid Tumors (clinicaltrials.gov) -  Feb 28, 2023   
    P2,  N=100, Recruiting, 
    Adequate management of comorbidities and AEs increases treatment tolerability and minimizes dose reductions. Trial completion date: Jan 2025 --> Jan 2027 | Trial primary completion date: Jan 2023 --> Jan 2025
  • ||||||||||  Keytruda (pembrolizumab) / Merck (MSD), Lenvima (lenvatinib) / Eisai, Merck (MSD)
    Enrollment open, Metastases:  LaPemERLA: Phase II Lenvatinib and Pembrolizumab in Endocrine Resistant Breast Cancer With Letrozole (clinicaltrials.gov) -  Feb 27, 2023   
    P2,  N=40, Recruiting, 
    It might be capable of sifting out patients who benefit from adjuvant therapy after LT for HCC, providing a reliable tool for precise clinical decision-making of patients with HCC with LT. Not yet recruiting --> Recruiting
  • ||||||||||  Lenvima (lenvatinib) / Eisai, Merck (MSD)
    Preclinical, Journal:  NEAT1-SOD2 Axis Confers Sorafenib and Lenvatinib Resistance by Activating AKT in Liver Cancer Cell Lines. (Pubmed Central) -  Feb 24, 2023   
    Although NEAT1 or SOD2 knockdown enhanced endoplasmic reticulum (ER) stress, concomitant with the suppression of AKT, taurodeoxycholate, an ER stress suppressor, did not restore AKT activity. Although further in vivo and clinical studies are needed, these results suggested that NEAT1v1 switches the growth modality of liver cancer cell lines from MEK/ERK-dependent to AKT-dependent mode via SOD2 and regulates sensitivity to the molecular-targeted drugs independent of ER stress.
  • ||||||||||  Lenvima (lenvatinib) / Eisai, Merck (MSD)
    Journal:  Analysis on Efficacy of Hepatic Artery Infusion Chemotherapy with or without Lenvatinib for Unresectable Hepatocellular Carcinoma. (Pubmed Central) -  Feb 24, 2023   
    Although further in vivo and clinical studies are needed, these results suggested that NEAT1v1 switches the growth modality of liver cancer cell lines from MEK/ERK-dependent to AKT-dependent mode via SOD2 and regulates sensitivity to the molecular-targeted drugs independent of ER stress. Combination therapy of HAIC and lenvatinib notably performed better than the HAIC monotherapy in patients with unresectable HCC in terms of ORR and was well tolerated, which deserves further investigation with large-scale clinical trials.
  • ||||||||||  Lenvima (lenvatinib) / Eisai, Merck (MSD)
    Journal:  Lenvatinib inhibits intrahepatic cholangiocarcinoma via Gadd45a-mediated cell cycle arrest. (Pubmed Central) -  Feb 23, 2023   
    Combination therapy of HAIC and lenvatinib notably performed better than the HAIC monotherapy in patients with unresectable HCC in terms of ORR and was well tolerated, which deserves further investigation with large-scale clinical trials. Our work first found that lenvatinib exerted an excellent antitumor effect
  • ||||||||||  Lenvima (lenvatinib) / Eisai, Merck (MSD)
    Trial completion date, Trial primary completion date, Metastases:  Lenvatinib for Advanced Bone and Soft Tissue Sarcoma (clinicaltrials.gov) -  Feb 17, 2023   
    P2,  N=60, Not yet recruiting, 
    Trial completion date: Dec 2024 --> Apr 2027 | Trial primary completion date: Dec 2024 --> Apr 2027 Trial completion date: Jun 2025 --> Dec 2026 | Trial primary completion date: Jun 2025 --> Dec 2026
  • ||||||||||  Keytruda (pembrolizumab) / Merck (MSD), Lenvima (lenvatinib) / Eisai, Merck (MSD)
    New P1 trial:  Neoadjuvant Pembrolizumab and Lenvatinib for Renal Cell Carcinoma (clinicaltrials.gov) -  Feb 17, 2023   
    P1,  N=30, Not yet recruiting, 
  • ||||||||||  Lenvima (lenvatinib) / Eisai, Merck (MSD)
    Enrollment change, Trial withdrawal, Metastases:  Safety and Efficacy of Radiation Plus TACE and Lenvatinib in Advanced HCC With PVTT (clinicaltrials.gov) -  Feb 16, 2023   
    P=N/A,  N=0, Withdrawn, 
    Trial completion date: Jun 2025 --> Dec 2026 | Trial primary completion date: Jun 2025 --> Dec 2026 N=100 --> 0 | Recruiting --> Withdrawn
  • ||||||||||  Lenvima (lenvatinib) / Eisai, Merck (MSD)
    Add-on Gefitinib for Unresectable Hepatocellular Carcinoma after Lenvatinib Failure (2nd floor Poster Area - 244) -  Feb 15, 2023 - Abstract #APASL2023APASL_799;    
    Lenvatinib is the key multi-kinase inhibitor (MKI) by targeting not only vascular endothelial growth factor receptors (VEGFR)1-3 but also fibroblast growth factor receptors (FGFR)1-4 for unresectable hepatocellular carcinoma (uHCC) with a better objective response rate (ORR) and non-inferiority in overall survival as compared with sorafenib...Of them, 2 received lenvatinib monotherapy and the other 11 used lenvatinib/pembrolizumab combinations...Further analysis by more patient numbers and longer follow-up duration is still required. 1072
  • ||||||||||  Keytruda (pembrolizumab) / Merck (MSD), Lenvima (lenvatinib) / Eisai, Merck (MSD)
    Trial completion date, Trial primary completion date:  Lenvatinib and Pembrolizumab in Differentiated Thyroid Cancers (DTC) (clinicaltrials.gov) -  Feb 14, 2023   
    P2,  N=60, Active, not recruiting, 
    Valuable ML radiomics models were constructed, with favorable performance in predicting the response to lenvatinib monotherapy for unresectable HCC. Trial completion date: Sep 2024 --> Oct 2023 | Trial primary completion date: Oct 2023 --> Aug 2022
  • ||||||||||  Lenvima (lenvatinib) / Eisai, Merck (MSD)
    Tumor-targeting NHC-Au(I) complex which induces immunogenic cell death in hepatocellular carcinoma (Virtual Session (Virtual Only)) -  Feb 14, 2023 - Abstract #ACSSp2023ACS_SP_10883;    
    Among these, complex 4C exhibits the excellent effectiveness for tumor targeting and antitumor activity, induce the occurrence of ICD in HCC cells, and has a good inhibitory effect on lenvatinib (first-line clinical treatment for advanced HCC patients) resistant cell lines...More importantly, 4C shows a great ICD-inducing effect in a vaccination mouse model and leads to activate antitumor immunity in tumor-bearing C57/BL6 mouse model. In conclusion, we show the potential of Au(I) complex with HCC-targeted capabilities for effective tumor immunotherapy.
  • ||||||||||  Keytruda (pembrolizumab) / Merck (MSD), Lenvima (lenvatinib) / Eisai, Merck (MSD)
    Trial completion date, Trial initiation date, Trial primary completion date, Metastases:  Pembrolizumab and Lenvatinib After Definitive Chemoradiation of Locally Advanced HNSCC (clinicaltrials.gov) -  Feb 13, 2023   
    P2,  N=47, Not yet recruiting, 
    In conclusion, we show the potential of Au(I) complex with HCC-targeted capabilities for effective tumor immunotherapy. Trial completion date: Apr 2026 --> Sep 2026 | Initiation date: Oct 2022 --> Mar 2023 | Trial primary completion date: Apr 2024 --> Sep 2025
  • ||||||||||  Stivarga (regorafenib) / Bayer, Lenvima (lenvatinib) / Eisai, Merck (MSD)
    Biomarker, Review, Journal, Tumor microenvironment:  The Roles of Epigenetic Regulation and the Tumor Microenvironment in the Mechanism of Resistance to Systemic Therapy in Hepatocellular Carcinoma. (Pubmed Central) -  Feb 12, 2023   
    Elucidation of the mechanisms underlying the resistance to systemic therapies and the appropriate response strategies to solve this issue will contribute to improved outcomes in the multidisciplinary treatment of uHCC. In this review, we summarize recent findings on the mechanisms of resistance to drugs such as sorafenib, regorafenib, and lenvatinib in molecularly targeted therapy, with a focus on epigenetic regulation and the tumor microenvironment and outline the approaches to improve the therapeutic outcome for patients with advanced HCC.